Approval builds on established role of Rhapsido in CSU and highlights potential of BTK inhibition across immune-mediated ...
Novartis achieved Tier 1 status in the 2026 Corporate Mental Health Benchmark, recognizing its approach to workplace mental ...
Community health starts with trust. See how Novartis and The Balm In Gilead are helping connect more people access cancer ...
About Novartis Neuroscience Neurological diseases are deeply personal, affecting people of any age, from newborns to seniors, often striking in the prime of life. In multiple sclerosis (MS), Novartis ...
. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result ...
Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ...
The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs. Most medicines are made the old-fashioned way. In ...
Audit & Finance BD&L & Strategic Planning Commercial & General Management Communications & Public Affairs Data and Digital Facilities & Administration Human Resources Information Technology ...
An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With ...
Explore opportunities with Novartis below.
Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer, Novartis US, responsible for the expansion of medicines across oncology, immunology, neurology, and cardiovascular, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results